- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01132313
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
Safety, Antiviral Effect and Pharmacokinetics of BI 207127 in Combination With BI 201335 and With or Without Ribavirin for 4, 16, 24, 28 or 40 Weeks in Patients With Chronic HCV Genotype 1 Infection (Randomized Phase Ib/II)
The substances BI 201335 and BI 207127 are being developed for the treatment of chronic hepatitis C virus infection. BI 201335 and BI 207127 work by preventing the virus from replicating.
The currently available medications pegylated interferon alfa and ribavirin for hepatitis C ca have considerable adverse events in patients and in many cases are not sufficiently effective. This is particularly the case in treatment of patients infected with genotype 1 of HCV.
A combination therapy of these new substances without pegylated interferon alfa may be associated with fewer adverse events that currently available (pegylated interferon-alfa-based) medication and may also provide a treatment option to the large number of patients with contraindications or intolerance to pegylated interferon alfa.
This clinical trial (1241.21) currently consists of 3 distinct studies: Part 1, Part 2 and Part 3.
Part 1 (SOUND-C1) is a 2 armed study as described in experimental arms 1 and 2 below (actual enrollment: 56 patients; randomized and treated: 32) Part 2 (SOUND-C2) is a 5 armed study as described in experimental arms 3 to 7 below (actual enrollment: 465; randomized and treated: 362) Part 3 (SOUND-C3) includes 3 arms as described in experimental arms 8 to 10 below (83 patients randomized and treated)
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
Victoria
-
Heidelberg, Victoria, Austrálie
- 1241.21.61002 Boehringer Ingelheim Investigational Site
-
Melbourne, Victoria, Austrálie
- 1241.21.61001 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Clichy, Francie
- 1241.21.33005 Boehringer Ingelheim Investigational Site
-
Grenoble cédex 9, Francie
- 1241.21.33007 Boehringer Ingelheim Investigational Site
-
Lyon, Francie
- 1241.21.33003 Boehringer Ingelheim Investigational Site
-
Marseille, Francie
- 1241.21.33001 Boehringer Ingelheim Investigational Site
-
Montpellier, Francie
- 1241.21.33002 Boehringer Ingelheim Investigational Site
-
Paris, Francie
- 1241.21.33004 Boehringer Ingelheim Investigational Site
-
Paris, Francie
- 1241.21.33008 Boehringer Ingelheim Investigational Site
-
Vandoeuvre Cedex, Francie
- 1241.21.33006 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Auckland NZ, Nový Zéland
- 1241.21.64001 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Berlin, Německo
- 1241.21.49002 Boehringer Ingelheim Investigational Site
-
Berlin, Německo
- 1241.21.49003 Boehringer Ingelheim Investigational Site
-
Düsseldorf, Německo
- 1241.21.49007 Boehringer Ingelheim Investigational Site
-
Esslingen, Německo
- 1241.21.49005 Boehringer Ingelheim Investigational Site
-
Frankfurt am Main, Německo
- 1241.21.49001 Boehringer Ingelheim Investigational Site
-
Hamburg, Německo
- 1241.21.49006 Boehringer Ingelheim Investigational Site
-
Hannover, Německo
- 1241.21.49009 Boehringer Ingelheim Investigational Site
-
Leipzig, Německo
- 1241.21.49004 Boehringer Ingelheim Investigational Site
-
Mainz, Německo
- 1241.21.49008 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Aveiro, Portugalsko
- 1241.21.35103 Boehringer Ingelheim Investigational Site
-
Coimbra, Portugalsko
- 1241.21.35104 Boehringer Ingelheim Investigational Site
-
Lisboa, Portugalsko
- 1241.21.35101 Boehringer Ingelheim Investigational Site
-
Lisboa, Portugalsko
- 1241.21.35105 Boehringer Ingelheim Investigational Site
-
Porto, Portugalsko
- 1241.21.35102 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Linz, Rakousko
- 1241.21.43003 Boehringer Ingelheim Investigational Site
-
Wien, Rakousko
- 1241.21.43001 Boehringer Ingelheim Investigational Site
-
Wien, Rakousko
- 1241.21.43002 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bucharest, Rumunsko
- 1241.21.40001 Boehringer Ingelheim Investigational Site
-
Bucharest, Rumunsko
- 1241.21.40002 Boehringer Ingelheim Investigational Site
-
Bucharest, Rumunsko
- 1241.21.40003 Boehringer Ingelheim Investigational Site
-
-
-
-
California
-
La Jolla, California, Spojené státy
- 1241.21.0003 Boehringer Ingelheim Investigational Site
-
San Diego, California, Spojené státy
- 1241.21.0006 Boehringer Ingelheim Investigational Site
-
San Francisco, California, Spojené státy
- 1241.21.0004 Boehringer Ingelheim Investigational Site
-
-
Florida
-
Palm Harbor, Florida, Spojené státy
- 1241.21.0011 Boehringer Ingelheim Investigational Site
-
-
Indiana
-
Valparaiso, Indiana, Spojené státy
- 1241.21.0013 Boehringer Ingelheim Investigational Site
-
-
Massachusetts
-
Springfield, Massachusetts, Spojené státy
- 1241.21.0008 Boehringer Ingelheim Investigational Site
-
-
North Carolina
-
Fayetteville, North Carolina, Spojené státy
- 1241.21.0019 Boehringer Ingelheim Investigational Site
-
-
Texas
-
Arlington, Texas, Spojené státy
- 1241.21.0012 Boehringer Ingelheim Investigational Site
-
Austin, Texas, Spojené státy
- 1241.21.0005 Boehringer Ingelheim Investigational Site
-
Dallas, Texas, Spojené státy
- 1241.21.0007 Boehringer Ingelheim Investigational Site
-
Houston, Texas, Spojené státy
- 1241.21.0010 Boehringer Ingelheim Investigational Site
-
-
Washington
-
Seattle, Washington, Spojené státy
- 1241.21.0017 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Barcelona, Španělsko
- 1241.21.34002 Boehringer Ingelheim Investigational Site
-
Barcelona, Španělsko
- 1241.21.34005 Boehringer Ingelheim Investigational Site
-
Madrid, Španělsko
- 1241.21.34003 Boehringer Ingelheim Investigational Site
-
Madrid, Španělsko
- 1241.21.34004 Boehringer Ingelheim Investigational Site
-
Majadahonda-Madrid, Španělsko
- 1241.21.34001 Boehringer Ingelheim Investigational Site
-
Valencia, Španělsko
- 1241.21.34006 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Basel, Švýcarsko
- 1241.21.41003 Boehringer Ingelheim Investigational Site
-
Bern, Švýcarsko
- 1241.21.41006 Boehringer Ingelheim Investigational Site
-
St. Gallen, Švýcarsko
- 1241.21.41001 Boehringer Ingelheim Investigational Site
-
Zürich, Švýcarsko
- 1241.21.41002 Boehringer Ingelheim Investigational Site
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion criteria:
- Chronic hepatitis C virus (HCV) infection of genotype (GT) 1
- Parts 1-3:Treatment naive to Interferon -alfa (IFN), Pegylated interferon -alfa (PegIFN), ribavirin (RBV), and any direct acting antiviral agent for chronic hepatitis C
- Part 4: Treatment experienced with confirmed prior virological failure to an approved dose of PegIFN/RBV (null-response)
- HCV RNA >=10,000 IU/mL at screening
- Liver biopsy within two years or fibroscan within six months prior to baseline
- Liver biopsy within two years or fibroscan within 6 months prior to screening
- Age 18-75 years
Exclusion criteria:
- Hepatitis C virus (HCV) infection of mixed genotype
- Evidence of liver disease due to causes other than chronic HCV infection
- Positive ELISA for human immunodeficiency virus (HIV)
- Hepatitis B virus (HBV) infection
- Decompensated liver disease or history of decompensated liver disease
- Active or suspected malignancy within the last 5 years
- Ongoing or historical photosensitivity or recurrent rash
- History of alcohol or drug abuse (except cannabis) within the past 12 months
- Body mass index (BMI)I <18 or > 35 kg/m2
- Usage of any investigational drugs within 30 days prior to enrolment, or 5 half-lives, whichever is longer; o the planned usage of an investigational drug during the course of the current study
- Known hypersensitivity to any ingredient of the study drugs
- A condition that is defined as one which in the opinion of the investigator may interfere with the patient's capability for participation in the trial or may influence the results of the trial
- Alpha fetoprotein >100ng/mL at screening; if >20ng/mL and <=100ng/mL, patients can be included if there is no evidence of liver cancer in an appropriate imaging study within 6 months prior to randomisation
- Total bilirubin > 2 mg/dL with ratio of direct/indirect > 1
- AST or ALT >5xULN
- INR prolonged to >1.7xULN
- Requirement for chronic systemic corticosteroids
- Received concomitant systemic antiviral, hematopoietic growth factor, or immunomodulatory treatment within 30 days prior to enrolment or 5 half-lives, whichever is longer
- Received silymarin or glycyrrhizin or Sho-saiko-to within 30 days prior to enrolment
- Contraindications pertaining to PegIFN or RBV
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: 2
4 weeks of high dose TID BI 207127 and QD BI 201335 in combination with RBV, Part 1
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
Experimentální: 1
4 weeks of low dose three times per day (TID) BI 207127 and once daily (QD) BI 201335 in combination with RBV, Part 1
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
Experimentální: 3
16 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
Experimentální: 4
28 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
Experimentální: 5
40 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
Experimentální: 6
28 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 2
|
40 weeks, QD
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
48 weeks, according to label
40 weeks, according to label
28 weeks, QD
16 weeks, QD
24 weeks, according to label
28 weeks, high dose BID
|
Experimentální: 7
28 weeks of TID BI 207127 and QD BI 201335 without RBV, Part 2
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
Experimentální: 8
16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
Experimentální: 9
24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
Experimentální: 10
24 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 3
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
Experimentální: 11
16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
Experimentální: 12
24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Part 1: Rapid Virological Response (RVR)
Časové okno: 4 weeks
|
Part 1: Rapid virological response (RVR), defined as Hepatitis C Virus Ribonucleic acid (HCV RNA) <25IU/mL at Week 4 of treatment
|
4 weeks
|
Part 2: Sustained Virological Response (SVR)
Časové okno: From drug administration until 12 weeks after end of treatment, up to 52 weeks
|
Part 2: Sustained virological response (SVR), defined as HCV RNA <25 IU/mL and undetectable at 12 weeks after end of treatment
|
From drug administration until 12 weeks after end of treatment, up to 52 weeks
|
Part 3 and 4: Sustained Virological Response (SVR)
Časové okno: From drug administration until 12 weeks after end of treatment, up to 36 weeks
|
Part 3 and 4: Sustained virological response (SVR) defined as HCV RNA <25IU/mL and undetectable at 12 weeks after end of treatment
|
From drug administration until 12 weeks after end of treatment, up to 36 weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Part 1: Time to Virological Response
Časové okno: From drug administration until end of drug administration, up to 4 weeks
|
Part 1: Time to virological response, defined as the timepoint of the first measurement of plasma HCV RNA level <25 IU/mL.
The percentage of participants who achieved virological response within each time period are displayed for this outcome measure.
|
From drug administration until end of drug administration, up to 4 weeks
|
Part 2: Time to Virological Response
Časové okno: From drug administration until end of drug administration, up to 40 weeks
|
Part 2: Time to virological response, defined as the timepoint of the first measurement of plasma HCV RNA level <25 IU/mL.
The percentage of participants who achieved virological response within each time period are displayed for this outcome measure.
|
From drug administration until end of drug administration, up to 40 weeks
|
Part 1 and 2: Plasma HCV RNA Level Not Detectable at Week 4
Časové okno: 4 weeks
|
Part 1 and 2: Plasma Hepatitis C Virus Ribonucleic acid (HCV RNA) level not detectable at Week 4
|
4 weeks
|
Part 2: Sustained Virological Response at 4 and 24 Weeks After End of Treatment
Časové okno: 4 weeks and 24 weeks after the end of treatment, up to 64 weeks
|
Part 2: Sustained virological response at 4 and 24 weeks after end of treatment
|
4 weeks and 24 weeks after the end of treatment, up to 64 weeks
|
Part 3 and 4: Plasma HCV RNA Level <25 IU/mL at Week 4 and 12 of Treatment
Časové okno: Week 4 and 12
|
Part 3 and 4: Plasma Hepatitis C Virus Ribonucleic acid (HCV RNA) level <25 IU/mL at week 4 and 12 of treatment
|
Week 4 and 12
|
Part 3 and 4: Sustained Virological Response (SVR) at 4 Weeks After End of Treatment
Časové okno: up to 28 weeks
|
Part 3 and 4: Sustained virological response (SVR) at 4 weeks after end of treatment
|
up to 28 weeks
|
Spolupracovníci a vyšetřovatelé
Sponzor
Publikace a užitečné odkazy
Obecné publikace
- Zeuzem S, Mantry P, Soriano V, Buynak RJ, Dufour JF, Pockros PJ, Wright D, Angus P, Buti M, Stern JO, Kadus W, Vinisko R, Bocher W, Mensa FJ. Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. Eur J Gastroenterol Hepatol. 2016 Aug;28(8):923-6. doi: 10.1097/MEG.0000000000000649.
- Asselah T, Zeuzem S, Soriano V, Bronowicki JP, Lohse AW, Mullhaupt B, Schuchmann M, Bourliere M, Buti M, Roberts SK, Gane EJ, Stern JO, Voss F, Baum P, Gallivan JP, Bocher WO, Mensa FJ. ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. PLoS One. 2015 Dec 9;10(12):e0144004. doi: 10.1371/journal.pone.0144004. eCollection 2015.
- Zeuzem S, Soriano V, Asselah T, Gane EJ, Bronowicki JP, Angus P, Lohse AW, Stickel F, Mullhaupt B, Roberts S, Schuchmann M, Manns M, Bourliere M, Buti M, Stern JO, Gallivan JP, Voss F, Sabo JP, Bocher W, Mensa FJ; SOUND-C2 Study Group. Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis. Antimicrob Agents Chemother. 2015 Feb;59(2):1282-91. doi: 10.1128/AAC.04383-14. Epub 2014 Dec 15.
- Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Mullhaupt B, Schuchmann M, Bourliere M, Buti M, Roberts SK, Gane EJ, Stern JO, Vinisko R, Kukolj G, Gallivan JP, Bocher WO, Mensa FJ. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med. 2013 Aug 15;369(7):630-9. doi: 10.1056/NEJMoa1213557.
- Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Mullhaupt B, Gane E, Schuchmann M, Lohse AW, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Nehmiz G, Kukolj G, Bocher WO, Mensa FJ. Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antivir Ther. 2013;18(8):1015-9. doi: 10.3851/IMP2567. Epub 2013 Apr 4.
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Nemoci trávicího systému
- RNA virové infekce
- Virová onemocnění
- Infekce
- Infekce přenášené krví
- Přenosné nemoci
- Onemocnění jater
- Infekce Flaviviridae
- Hepatitida, virová, lidská
- Hepatitida, chronická
- Hepatitida
- Hepatitida C
- Hepatitida C, chronická
- Molekulární mechanismy farmakologického působení
- Antiinfekční látky
- Antivirová činidla
- Antimetabolity
- Ribavirin
Další identifikační čísla studie
- 1241.21
- 2009-018197-66 (Číslo EudraCT: EudraCT)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Hepatitida C, chronická
-
National Taiwan University Hospital Hsin-Chu BranchNeznámýSelhání přístupu k hemodialýze | Krevní tlak | Porucha přístupu k dialýzeTchaj-wan
-
National Research Centre, EgyptFaculty of Medicine, Minia UniversityDokončeno
-
University of OttawaZatím nenabírámeAbsorpce pneumokokové vakcíny | Ochota k očkování | Znalost pneumokokové vakcíny | Postoj k vakcíně proti pneumokokůmKanada
-
University of LouisvilleKentucky Cabinet for Health & Family ServicesDokončenoOvládání seznamu čekatelů | Učební plán výchovy k rodičovství | Kurikulum výchovy k rodičovství + Case ManagementSpojené státy
-
Izmir University of EconomicsThe Scientific and Technological Research Council of TurkeyNáborNesnášenlivost k nejistotěKrocan
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceDokončeno
-
Centre d'Investigation Clinique et Technologique...National Research Agency, FranceDokončenoPostoj k počítačůmFrancie
-
Hospital for Special Surgery, New YorkDokončenoPřipravenost k vybitíSpojené státy
-
Maastricht University Medical CenterDokončeno
-
National Cancer Institute (NCI)Aktivní, ne náborRakovina | Dědičné novotvary | Genetická predispozice k rakovině | Životní prostředíSpojené státy
Klinické studie na BI 207127
-
Boehringer IngelheimDokončeno
-
Boehringer IngelheimDokončeno
-
Boehringer IngelheimUkončenoRenální insuficienceNěmecko
-
Boehringer IngelheimDokončeno
-
Boehringer IngelheimDokončeno
-
Boehringer IngelheimDokončenoHepatitida C, chronickáFrancie, Německo, Švýcarsko
-
Boehringer IngelheimDokončeno
-
Boehringer IngelheimUkončeno
-
Boehringer IngelheimDokončeno
-
Boehringer IngelheimDokončenoHepatitida C, chronickáSpojené státy, Německo, Španělsko, Spojené království